Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...

Segal Trials, a privately held clinical research network specializing in acute schizophrenia and other psychiatric disorders, ...

Previously, clinical research findings on cadonilimab in the treatment of various malignancies have been published in internationally renowned journals such as The Lancet, The Lancet Oncology, Nature ...

Stuart Therapeutics completed a Phase 3 trial for ST-100, a treatment for dry eye disease, involving a randomized, ...

NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Cebranopadol is an investigational dual-nociceptin/orphanin FQ peptide receptor and µ-opioid peptide receptor agonist.

Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX), a clinical ...

The Phase II trial conducted by the Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in Warsaw, the national reference centre for STS in Poland, has reached its enrolment ...

CHICAGO, IL / ACCESS Newswire / January 22, 2025 / ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company with a market capitalization of $1.6 billion focused on developing innovative therapies for challenging diseases, has been making ...